BRCA1 and neoplasm: In cfDNA samples from the period preceding the diagnosis of mUC, our own tumor-informed re-alignment and re-analysis found the TP53 G245D and BRCA1 N1521fs mutations to be present 12 (at least) and 8 months, respectively, prior to their earliest appearance in the clinical reports, at VAFs of 0.24% and 0.04%, respectively.